Abstract
Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.
Highlights
Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19)
Given weekly as 180 mcg subcutaneous injections, has comparable antiviral efficacy and an improved tolerability profile compared with type I IFN for the treatment of hepatitis[23], likely due to its relatively limited receptor distribution
We show that a single subcutaneous injection of Lambda in outpatients with uncomplicated SARS-CoV-2 infection did not significantly reduce time to viral clearance or resolution of symptoms compared with placebo
Summary
Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We show that a single subcutaneous injection of Lambda in outpatients with uncomplicated SARS-CoV-2 infection did not significantly reduce time to viral clearance or resolution of symptoms compared with placebo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.